Conference Coverage

Migraine treatment insights offered for noninvasive vagus nerve stimulation


 

EXPERT ANALYSIS FROM THE AHS ANNUAL MEETING

Using the nVNS device

This nVNS device produces a proprietary, low-voltage electrical signal with a 24-volt peak voltage and a 60-mA peak output current. In the PRESTO study, patients were instructed to self-administer bilateral 120-second stimulations to the right and left sides of their necks within 20 minutes of pain onset. If the pain hadn’t improved within 15 minutes, they were to repeat the stimulations.

In a post hoc analysis of the PREVA (Prevention and Acute treatment of chronic cluster headache) study (Cephalalgia. 2016;36[6]:534-46), investigators determined that the mean reduction in the number of cluster headache attacks was significantly greater in patients who used the device to treat at least 77% of their attacks. That had a bigger preventive effect than did the number of stimulations a patient applied per day.

The PRESTO and PREVA trials were sponsored by electroCore, where Mr. Liebler is employed.

Pages

Recommended Reading

CDC: Marijuana use may spur industries to rethink current policies
Clinician Reviews
Endometriosis pain stemming from pelvic spasms improved with botulinum toxin
Clinician Reviews
Beware nonopiate meds with high street value
Clinician Reviews
Cluster headache presents differently in never-smokers, survey finds
Clinician Reviews
The Evidence for Herbal and Botanical Remedies
Clinician Reviews
Treating Migraines: It’s Different for Kids
Clinician Reviews
All-Terrain, No Control
Clinician Reviews
Fremanezumab may be an effective episodic migraine treatment
Clinician Reviews
Getting Ahead of the Pain
Clinician Reviews
Migraine and menopause: Longitudinal study shows what to expect
Clinician Reviews